Domperidone
Brand names: Equidone ยท Active ingredient: Domperidone
In short: For prevention of fescue toxicosis in periparturient mares.
What is Domperidone used for?
For prevention of fescue toxicosis in periparturient mares.
โ Boxed warning (FDA's strongest warning)
Failure of passive transfer of immunoglobulins (IgG) may occur when using EQUIDONE Gel even in the absence of leakage of colostrum or milk. All foals born to mares treated with EQUIDONE Gel should be tested for serum IgG concentrations. Do not use in horses intended for human consumption.
Not for use in humans. For oral use in animals only. Keep this and all drugs out of the reach of children. Pregnant and lactating women should use caution when handling EQUIDONE Gel, as systemic exposure to domperidone may affect reproductive hormones. Domperidone is not approved for any indication in humans in the US. The safety of domperidone in lactating women and their nursing children has not been evaluated. Consult a physician in case of accidental human exposure.
Domperidone dosage
Orally administer 0.5 mg/lb (1.1 mg/kg) once daily starting 10 to 15 days prior to Expected Foaling Date (EFD). Treatment may be continued for up to 5 days after foaling if mares are not producing adequate milk after foaling.
Determine the appropriate dose for the body weight of the mare based on the dosing table below. One cc will treat 220 lb (100 kg) of body weight.
Table 1. Dosing Table
Weight(lb)
Weight(kg)
cc
Domperidone(mg)
550-660
250-300
3
330
661-880
301-400
4
440
881-1100
401-500
5
550
1101-1320
501-600
6
660
Turn the dial ring until the edge of the ring nearest the tip of the syringe lines up with the dose to be delivered.
Remove the syringe cap.
Make sure the horse's mouth is free of food or other obstructions.
Insert the nozzle of the syringe through the interdental space of the horse's mouth and deposit the gel on the back of the tongue by depressing the plunger.
Recap the syringe.
This is a 25 cc multi-dose syringe. Please note that for subsequent doses, it will be necessary to adjust for previous doses. For example, if the intended dose for a horse is 5 cc, then the dial ring is set at 5 cc for the first dose, at 10 cc for the second dose, at 15 cc for the third dose, at 20 cc for the fourth dose, and at 25 cc for the fifth dose.
Warnings & precautions
Do not take this medicine if: Horses with hypersensitivity to domperidone should not receive EQUIDONE Gel.
EQUIDONE Gel may lead to premature birth, low birth weight foals or foal morbidity if administered >15 days prior to the expected foaling date. Accurate breeding date(s) and an expected foaling date are needed for the safe use of EQUIDONE Gel. The safety of EQUIDONE Gel has not been evaluated in breeding, pregnant and lactating mares other than in the last 45 days of pregnancy and the first 15 days of lactation . The safety in stallions has not been evaluated. The long term effects on foals born to mares treated with EQUIDONE Gel have not been evaluated.
Do not use in horses with suspected or confirmed gastrointestinal blockage, as domperidone is a prokinetic drug (it stimulates gut motility).
Use of EQUIDONE Gel may cause a false positive on the milk calcium test used to predict foaling.
Domperidone is a known P-glycoprotein substrate1 and its main metabolic pathway in humans is through CYP3A4. Significant inhibition of domperidone metabolism may occur when co-administered with drugs such as erythromycin2 and ketoconazole3. This could result in significantly greater domperidone drug exposure (multi-fold increase) when used with these drugs.
Domperidone side effects
The most common adverse reactions associated with treatment with EQUIDONE Gel are premature lactation (dripping of milk prior to foaling) and failure of passive transfer.
In a laboratory effectiveness study with 32 periparturient mares (17 treated with EQUIDONE Gel and 15 treated with vehicle control) 3/17 (18%) mares treated with EQUIDONE Gel experienced premature lactation. In the 25 foals (16 foals of mares treated with EQUIDONE Gel and 9 foals of vehicle control mares) evaluated for passive transfer, failure of passive transfer occurred in 13/16 (81%) foals of mares treated with EQUIDONE Gel and 8/9 (89%) foals of control mares. Failure of passive transfer in foals of mares treated with EQUIDONE Gel was not solely due to physical loss of colostrum through premature lactation, because 77% of EQUIDONE Gel treated mares that did not drip milk prior to foaling had foals with failure of passive transfer.
In a field study with 279 periparturient mares treated with EQUIDONE Gel, premature lactation was reported in 3 mares (1%) and failure of passive transfer was reported in 3 foals (1%).
In two additional field studies, a total of 2,556 mares were treated with EQUIDONE Gel or a bioequivalent formulation for 2,730 breeding seasons. Horses in these studies were treated with EQUIDONE Gel for varying durations. โฆ
About this medicine
Domperidone is a D2 dopamine receptor antagonist. Chemically, domperidone is 6-chloro-3-[1-[3-(2-oxo-3H-benzimidazol-1-yl)propyl]piperidin-4-yl]-1H-benzimidazol-2-one. The structural formula is:
How it works: Domperidone is a D2 dopamine receptor antagonist that blocks the agonistic action of fescue alkaloids at the cellular level. Unlike other D2 antagonist drugs, domperidone does not readily cross the blood-brain barrier4. Distribution studies with radio-labeled drug in animals have shown wide tissue distribution, but low brain concentration.
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID e55d075e-2fe2-4405-b57a-59b85067e0c0. Read the full official label on DailyMed.